– Pivotal Phase III IMbrave050 study investigating Tecentriq plus Avastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of ...
BOSTON (AP) - Avastin, the blockbuster drug that just lost approval for treating breast cancer, now looks disappointing against ovarian cancer, too. Two studies find that it does not improve survival ...
Fatal side effects were 1.5 times more frequent among patients on Avastin plus chemotherapy than among those getting chemotherapy alone.The highest risk was seen in patients with prostate and lung ...
A new study has linked Genentech's cancer drug Avastin to a higher rate of deadly side effects, the Wall Street Journal reports. The analysis, conducted by researchers at Stony Brook University ...
CHICAGO • A new analysis raises fresh questions about the risks of the blockbuster cancer drug Avastin, suggesting the chance of dying from side effects linked to it is higher than the risk for ...
MILAN (Reuters) - Roche's blockbuster drug Avastin helps women with ovarian cancer live longer without their disease getting worse, but its effect peaks at 12 months and then diminishes, researchers ...
The benefit obtained from Keytruda plus chemotherapy in patients with persistent, recurrent or metastatic cervical cancer occurred regardless of whether they also received Avastin. Patients with ...
The FDA’s approval of Vegzelma was based on data that demonstrated the biosimilar elicited comparable safety and efficacy to Avastin in several studies. The Food and Drug Administration (FDA) approved ...
(Reuters) - The U.S. Department of Veterans Affairs said it has stopped using Roche's Avastin to treat a sight-robbing eye disease as it looks into reports of increased risk of infection. Roche's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback